Skip to main content

Table 6 Changes in baseline to endpoint measures for sex hormones levels in two groups

From: Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome

Variables Mean ± SD
Placebo(n = 28)
Mean ± SD
Ellagic acid (n = 29)
P1
FSH (ng/ml) Baseline 6 ± 1.85 6.02 ± 1.91 0.57
End 6.01 ± 1.73 6.07 ± 1.9 0.601
P2 0.55 0.49  
Mean Changes 0.01 ± 0.12 0.05 ± 0.01 0.68
LH (ng/ml) Baseline 10.51 ± 2.19 10.84 ± 2.1 0.601
End 10.83 ± 2.02 9.73 ± 2.4 0.073
P2 0.58 0.076  
Mean Changes 0.32 ± 0.17 -1.11 ± 0.3 0.079
Total Testosterone (ng/ml) Baseline 0.6 ± 0.031 0.58 ± 0.023 0.61
End 0.59 ± 0.04 0.38 ± 0.017 0.038
P2 0.521 0.04  
Mean Changes -0.01 ± 0.09 -0.2 ± 0.06 0.042
Prolactin (ng/ml) Baseline 19.08 ± 4.5 19.91 ± 4.07 0.73
End 19 ± 4.11 12.3 ± 2.39 0.025
P2 0.671 0.036  
Mean Changes 0.32 ± 0.39 -7.61 ± 1.68 0.033
AMH (ng/ml) Baseline 12.02 ± 3.71 11.27 ± 3.07 0.43
End 11.9 ± 3.1 7.2 ± 1.01 0.036
P2 0.318 0.04  
Mean Changes -0.12 ± 0.61 -4.07 ± 2.06 0.045
  1. Data are expressed as means ± SD. FSH Follicle-stimulating hormone, LH Luteinizing hormone, AMH Anti-Mullerian hormone
  2. P1: Comparison of the mean of sex hormones between the two groups of Ellagic acid and placebo (Independent samples t-test)
  3. P2: Comparison of mean of sex hormones in each group at baseline and end of study (Paired samples t-test)